⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11312341 | 0.75 | — | — | |
| SCHEMBL6423804 | 0.75 | — | — | |
| SCHEMBL3547579 | 0.75 | — | — | |
| SCHEMBL18186102 | 0.75 | — | — | |
| SCHEMBL9853417 | 0.72 | — | — | |
| SCHEMBL8576907 | 0.71 | — | — | |
| SCHEMBL28195334 | 0.71 | — | — | |
| SCHEMBL8518034 | 0.71 | — | — | |
| SCHEMBL9693368 | 0.71 | — | — | |
| SCHEMBL11090349 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4214200-A1 | LANCL LIGANDS | Nimmune Biopharma, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-113748109-B | Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands | 朗多生物制药股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116368133-A | NLRX1 ligand | 朗多生物制药股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230167083-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-11459310-B2 | LANCL ligands | LANDOS BIOPHARMA, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| WO-2022087146-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220127250-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| CN-113748109-A | Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands | 朗多生物制药股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| EP-2266978-B1 | Novel physiologically active substances | EISAI R&D MAN CO LTD (JP) | 2015-05-20 | — | — | EP | disclosed |
| EP-1548121-B1 | Physiologically active substances | EISAI R&D MAN CO LTD (JP) | 2015-04-29 | — | — | EP | disclosed |
| US-20060241171-A1 | Novel physiologically active substances | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| US-20060235002-A1 | Novel physiologically active substance | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1710244-A1 | METHOD OF STABILIZING MACROLIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
| EP-1705247-A1 | DNA PARTICIPATING IN HYDROXYLATION OF MACROLIDE COMPOUND | MERCIAN CORPORATION (JP) | 2006-09-27 | — | — | EP | disclosed |
| US-20060009439-A1 | Novel physiologically active substances | MERCIAN CORPORATION (JP) | 2006-01-12 | — | — | US | disclosed |
| US-20050245514-A1 | Novel physiologically active substances | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| EP-1548121-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2005-06-29 | — | — | EP | disclosed |
| EP-1541570-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCE | MERCIAN CORPORATION (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1508570-A1 | NOVEL PHYSIOLGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2005-02-23 | — | — | EP | disclosed |